Developer docs
API playgroundTry for free, no card

Search company profiles

SureNano Science

Full company profile

uuid0003xea

Namestring
SureNano Science
Legal namestring
SureNano Science Ltd.
Websiteurl
surenano.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

SureNano Science is a Vancouver, BC-based life sciences and specialty chemicals company listed on the CSE under the ticker SURE (OTCQB: SURNF) since December 2021. The company has historically operated a surfactant and nano-emulsion business built around its proprietary SureNano Emulsifier technology, with FDA GRAS designation and Health Canada approvals supporting applications in food, beverage, and cosmetics. In early 2026 the company executed a strategic pivot into pharmaceutical development through the acquisition of GlucaPharm Inc., which holds exclusive development rights to GEP-44, a GLP-1 receptor agonist peptide originally licensed from Syracuse University. GEP-44 is in preclinical development, is advancing through FDA IND-enabling studies with LabCorp, and carries patent protection extending into 2042. The company is also pursuing adjacent opportunities including Ibogaine IP licensing. The company operates with a headcount in the 11–50 range and a market capitalization of approximately $9.8 million on 42 million-plus shares outstanding.

The business model spans two revenue streams with very different profiles. The legacy surfactant business generates cash via direct product sales — Emerald Scientific is the only named customer — and through narrow exclusive regional licensing arrangements covering Canada, Oklahoma, and Colorado. The pharmaceutical business is currently pre-revenue; GEP-44 and the Ibogaine program must clear IND-enabling studies, clinical trials (with planned execution in Australia), and regulatory approval before any product-related revenue can be realized, which places meaningful commercialization several years out at minimum. The company raised approximately $1.495M across two private placements in late 2025 to fund the pivot and early development, and has assembled a leadership team that includes CSO Dr. Nihar Pandey, scientific founders Dr. Doyle and Dr. Billing, and board appointee Doug Bachman.

SureNano serves two distinct customer sets: B2B specialty chemicals buyers in food, beverage, and cosmetics manufacturing, and — prospectively, post-approval — pharmaceutical partners, payers, and patients in the metabolic disease treatment market. The current revenue base is small and concentrated, the pharmaceutical pipeline is preclinical, and the company's near-term trajectory depends on continued capital formation and successful execution of the GEP-44 regulatory pathway rather than on the existing surfactant book of business.

Short descriptiontext

SureNano Science is a Vancouver-based life sciences company developing the GLP-1 peptide therapeutic GEP-44 (via GlucaPharm acquisition) alongside a legacy nano-emulsion surfactant business serving food, beverage, and cosmetics customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanoemulsion surfactants, drug delivery systems, GLP-1 therapeutics, metabolic disease peptides, food grade emulsifiers
Industry3 codes
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAJ
Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical & Drug Delivery Systems
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Surfactant Product Sales
TypeLicensing Royalties
Description

Sale and distribution of SureNano surfactant, a ready-to-mix food grade compound for nanoemulsions. Exclusive licensing agreements in Canada, Oklahoma, and Colorado generate product revenue.

surenano.com
2Pharmaceutical Licensing and Royalties
TypeLicensing Royalties
Description

Future revenue from licensing GEP-44 drug candidate to pharmaceutical partners. Revenue to be generated upon FDA approval and commercialization of metabolic therapeutics.

surenano.com
3Private Placement Financing
TypeOne Time License
Description

Capital raises through private placements to fund operations and development. December 2025 closing of $1,250,000 through issuance of units comprising common shares and warrants.

surenano.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1Licensing agreement with 20% royalty on net sales
ModelOtherBilling cadencePay-as-you-go
Notes

SureNano licenses surfactant distribution rights; licensee pays $10,000 upfront plus 20% quarterly royalty on all net sales for Oklahoma territory. 10-year term with renewal option.

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1GlucaPharm
Description

Subsidiary brand focused on developing next-generation GLP-1 pharmaceutical compounds including GEP-44 for obesity and metabolic disease.

surenano.com
+2 more records
Core offering1 text field

SureNano Science Ltd. is a publicly traded life sciences company operating two integrated lines: (1) a commercialized nanoemulsion surfactant platform — the FDA GRAS-approved, Health Canada-compliant SureNano Emulsifier and the in-development SureNano Powder — distributed through exclusive licenses in Canada and select US states; and (2) a pharmaceutical pipeline via its wholly owned subsidiary GlucaPharm Inc., anchored by GEP-44, a patented triple-agonist peptide (GLP-1 + Y1 + Y2) licensed from Syracuse University for obesity and metabolic disease, currently in FDA IND-enabling toxicology studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ~15% body weight reduction in preclinical obese rat studies vs ~9% for liraglutide
+3 more records
Product overview1 text field

SureNano Science Ltd. operates as a dual business entity: (1) A nanotechnology-enabled surfactant and delivery platform consisting of the SureNano™ Emulsifier (FDA GRAS-approved, Health Canada-approved liquid nanoemulsion) and SureNano™ Powder (in development); and (2) A pharmaceutical development pipeline anchored by the acquired subsidiary GlucaPharm Inc. and its lead asset GEP-44, a patented triple-agonist peptide therapeutic for obesity and metabolic disease. The company is transitioning from an enabling-technology company focused on drug delivery enhancement toward becoming a near-term pharmaceutical value creator in the GLP-1 metabolic market.

Product and service3 records
1SureNano™ Emulsifier
CategoryNanoemulsion Surfactant / Food Ingredient
Description

A 100% plant-derived, ready-to-mix food-grade stabilizing formula that delivers high-performance nanoemulsions for beverages, topical products, and consumables; maximizes bioavailability, clarity, and taste. Approved by FDA (GRAS) and Health Canada. Manufactured by Caldic under GFSI SQF, CFIA, and GMP quality systems. Distributed exclusively in Canada, Oklahoma (USA), and Colorado (USA).

2SureNano™ Powder
CategoryNanoemulsion Surfactant / Food Ingredient
Description

A powder-format nanoemulsion product in development that extends the SureNano surfactant line into dry-blend applications. Developed under a joint venture with 1150641 B.C. Ltd. with each joint venturer contributing $30,000 and exclusive license rights for Canada, Oklahoma, and Colorado.

3GEP-44 Triple Agonist Peptide Therapeutic
CategoryPeptide Therapeutics / Metabolic Disease Drug Candidate
Description

A patented monomeric peptide that acts as a triple agonist on GLP-1 and Peptide YY (PYY) receptors Y1 and Y2, intended for treatment of obesity, Type 2 diabetes, and metabolic disease. Demonstrated approximately 15% body weight reduction and 39% food intake reduction in preclinical studies with no GI side effects. Designed for oral, sublingual, or nasal non-injectable delivery. Patent-protected through 2042 (U.S. Patent Application 20220204581A1), exclusively licensed from Syracuse University.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-24
Description

Collaboration with premier global CRO LabCorp for GLP-compliant toxicology and pharmacology studies for GEP-44. Studies covering rodents and non-rodent primates to determine MTD, safety margins, and biomarkers for first-in-human studies.

2Academic Institutions and Research Groups (Ibogaine)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-24
Description

Early-stage discussions to license or acquire IP related to synthesis, formulation, and delivery of Ibogaine and next-generation analogues for mental health and addiction treatment.

surenano.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-23
Description

Six-month corporate communication and awareness strategy leveraging IBN's syndication network of over 5,000 media outlets, newsletters, social channels, and wire services. Quarterly cash consideration USD $29,000.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-23
Description

Enhanced news release distribution with news blast and forum boost advertising campaign. One-time cash fee of USD $10,000 plus applicable taxes.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-04-22
Description

Six-month investor outreach and awareness campaign. Distribution of sponsored content across leading financial websites, social platforms (X, Reddit, TikTok, LinkedIn), and multimedia content production. Total cash consideration USD $26,667.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-02-23
Description

Marketing and broadcast package including 30-second TV spot, TV ad spots, 40 BNN Bloomberg broadcasts, stock ticker ad, and newsletter eblast. Cash fee of $22,300 plus GST.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-01
Description

Emerald Scientific launched the SureNano Emulsifier product in 2020, developed over two years. Product is 100% plant-derived stabilizing formula for high-performance nanoemulsions.

Strategic tierCoreTypeTechnology or Integration
Description

Syracuse University researchers, led by Dr. Robert Doyle, discovered GEP-44 peptide technology. SureNano acquired GlucaPharm which holds exclusive license from Syracuse University for GEP-44 development. Research supported by NIH and other US entities.

91150641 B.C. Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture partner for development and marketing of SureNano powder nanoemulsion product. Each joint venturer contributed $30,000. Exclusive license agreements for Canada, Oklahoma, and Colorado.

surenano.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing peptide therapeutics for metabolic disease, including VK2735 (a dual GLP-1/GIP receptor agonist) for obesity. Highly comparable to SureNano/GlucaPharm as a small-cap, differentiated-mechanism GLP-1 developer pursuing the same end-market.

TypeDirect peer
Description

Clinical-stage company developing oral small-molecule GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and type 2 diabetes. Closely comparable to SureNano's GEP-44 strategy of pursuing a differentiated, non-injectable GLP-1 mechanism to compete with injectable incumbents.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing peptide therapeutics for metabolic disease, including pemvidutide, a GLP-1/glucagon dual agonist for obesity. Comparable as a small-cap peptide metabolic disease developer with similar clinical-stage positioning to GlucaPharm.

TypeDirect peer
Description

Denmark-based peptide therapeutics company developing multiple peptide candidates for metabolic disease and obesity, with a strong focus on differentiated mechanisms and non-injectable delivery. Directly comparable to GEP-44's peptide-mechanism, metabolic-disease focus.

TypeBroad incumbent
Description

Major pharmaceutical company and current market leader in the GLP-1 space with Mounjaro/Zepbound (tirzepatide, a dual GIP/GLP-1 agonist) and an extensive next-generation obesity/diabetes pipeline. Defines the competitive environment in which SureNano/GlucaPharm must compete.

TypeBroad incumbent
Description

Global leader in GLP-1 therapy with Ozempic and Wegovy (semaglutide) plus an oral GLP-1 (Rybelsus) and deep next-gen pipeline. Sets the efficacy, tolerability, and commercial benchmarks that any GEP-44 must meet or exceed to succeed.

TypeEmerging player
Description

Small-cap clinical-stage biotech focused on small-molecule drug discovery for metabolic and neuropathic disease. Comparable as an emerging player with limited resources pursuing differentiated metabolic-disease mechanisms.

TypeEmerging player
Description

Small-cap clinical-stage company developing therapeutics for rare metabolic disorders (e.g., Prader-Willi syndrome). Comparable profile to GlucaPharm as a micro-cap clinical-stage metabolic-disease developer with concentrated single-asset risk.

TypeBroad incumbent
Description

Global specialty chemicals company producing high-performance surfactants, formulation ingredients, and delivery systems for personal care, food, and life sciences markets. Comparable to SureNano's legacy nanoemulsion/surfactant business on the non-pharma side.

TypeOthers
Description

Distributor and channel partner that launched the SureNano Emulsifier product in 2020 and is a select customer for SureNano's surfactant line. Listed as an ecosystem/distribution peer rather than a competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SureNano Science

Pharmaceutical & Drug Delivery Systemssurenano.com

SureNano Science is a Vancouver-based life sciences company developing the GLP-1 peptide therapeutic GEP-44 (via GlucaPharm acquisition) alongside a legacy nano-emulsion surfactant business serving food, beverage, and cosmetics customers.

What SureNano Science does

SureNano Science is a Vancouver, BC-based life sciences and specialty chemicals company listed on the CSE under the ticker SURE (OTCQB: SURNF) since December 2021. The company has historically operated a surfactant and nano-emulsion business built around its proprietary SureNano Emulsifier technology, with FDA GRAS designation and Health Canada approvals supporting applications in food, beverage, and cosmetics. In early 2026 the company executed a strategic pivot into pharmaceutical development through the acquisition of GlucaPharm Inc., which holds exclusive development rights to GEP-44, a GLP-1 receptor agonist peptide originally licensed from Syracuse University. GEP-44 is in preclinical development, is advancing through FDA IND-enabling studies with LabCorp, and carries patent protection extending into 2042. The company is also pursuing adjacent opportunities including Ibogaine IP licensing. The company operates with a headcount in the 11–50 range and a market capitalization of approximately $9.8 million on 42 million-plus shares outstanding.

The business model spans two revenue streams with very different profiles. The legacy surfactant business generates cash via direct product sales — Emerald Scientific is the only named customer — and through narrow exclusive regional licensing arrangements covering Canada, Oklahoma, and Colorado. The pharmaceutical business is currently pre-revenue; GEP-44 and the Ibogaine program must clear IND-enabling studies, clinical trials (with planned execution in Australia), and regulatory approval before any product-related revenue can be realized, which places meaningful commercialization several years out at minimum. The company raised approximately $1.495M across two private placements in late 2025 to fund the pivot and early development, and has assembled a leadership team that includes CSO Dr. Nihar Pandey, scientific founders Dr. Doyle and Dr. Billing, and board appointee Doug Bachman.

SureNano serves two distinct customer sets: B2B specialty chemicals buyers in food, beverage, and cosmetics manufacturing, and — prospectively, post-approval — pharmaceutical partners, payers, and patients in the metabolic disease treatment market. The current revenue base is small and concentrated, the pharmaceutical pipeline is preclinical, and the company's near-term trajectory depends on continued capital formation and successful execution of the GEP-44 regulatory pathway rather than on the existing surfactant book of business.

SureNano Science firmographics

Firmographics
Name
SureNano Science
Legal name
SureNano Science Ltd.
Website
https://surenano.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
SureNano Science is a Vancouver-based life sciences company developing the GLP-1 peptide therapeutic GEP-44 (via GlucaPharm acquisition) alongside a legacy nano-emulsion surfactant business serving food, beverage, and cosmetics customers.
Ownership category
akta.pro rank

SureNano Science industry classification

Industry
Product category
Pharmaceutical & Drug Delivery Systems
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAJ
Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Nanoemulsion surfactants
  • Drug delivery systems
  • GLP-1 therapeutics
  • Metabolic disease peptides
  • Food grade emulsifiers

Where SureNano Science is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

SureNano Science business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Surfactant Product Sales: Sale and distribution of SureNano surfactant, a ready-to-mix food grade compound for nanoemulsions. Exclusive licensing agreements in Canada, Oklahoma, and Colorado generate product revenue.
  2. Pharmaceutical Licensing and Royalties: Future revenue from licensing GEP-44 drug candidate to pharmaceutical partners. Revenue to be generated upon FDA approval and commercialization of metabolic therapeutics.
  3. Private Placement Financing: Capital raises through private placements to fund operations and development. December 2025 closing of $1,250,000 through issuance of units comprising common shares and warrants.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLicensing agreement with 20% royalty on net sales

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

SureNano Science product offering

Product offering

Core offering

SureNano Science Ltd. is a publicly traded life sciences company operating two integrated lines: (1) a commercialized nanoemulsion surfactant platform — the FDA GRAS-approved, Health Canada-compliant SureNano Emulsifier and the in-development SureNano Powder — distributed through exclusive licenses in Canada and select US states; and (2) a pharmaceutical pipeline via its wholly owned subsidiary GlucaPharm Inc., anchored by GEP-44, a patented triple-agonist peptide (GLP-1 + Y1 + Y2) licensed from Syracuse University for obesity and metabolic disease, currently in FDA IND-enabling toxicology studies.

Product overview

SureNano Science Ltd. operates as a dual business entity: (1) A nanotechnology-enabled surfactant and delivery platform consisting of the SureNano™ Emulsifier (FDA GRAS-approved, Health Canada-approved liquid nanoemulsion) and SureNano™ Powder (in development); and (2) A pharmaceutical development pipeline anchored by the acquired subsidiary GlucaPharm Inc. and its lead asset GEP-44, a patented triple-agonist peptide therapeutic for obesity and metabolic disease. The company is transitioning from an enabling-technology company focused on drug delivery enhancement toward becoming a near-term pharmaceutical value creator in the GLP-1 metabolic market.

Differentiator

Problem solved

Functional benefit

Brands

  • GlucaPharm: Subsidiary brand focused on developing next-generation GLP-1 pharmaceutical compounds including GEP-44 for obesity and metabolic disease.
  • SureNano™ Emulsifier
  • SureNano™ Surfactant

Products and services

  • SureNano™ Emulsifier A 100% plant-derived, ready-to-mix food-grade stabilizing formula that delivers high-performance nanoemulsions for beverages, topical products, and consumables; maximizes bioavailability, clarity, and taste. Approved by FDA (GRAS) and Health Canada. Manufactured by Caldic under GFSI SQF, CFIA, and GMP quality systems. Distributed exclusively in Canada, Oklahoma (USA), and Colorado (USA).
  • SureNano™ Powder A powder-format nanoemulsion product in development that extends the SureNano surfactant line into dry-blend applications. Developed under a joint venture with 1150641 B.C. Ltd. with each joint venturer contributing $30,000 and exclusive license rights for Canada, Oklahoma, and Colorado.
  • GEP-44 Triple Agonist Peptide Therapeutic A patented monomeric peptide that acts as a triple agonist on GLP-1 and Peptide YY (PYY) receptors Y1 and Y2, intended for treatment of obesity, Type 2 diabetes, and metabolic disease. Demonstrated approximately 15% body weight reduction and 39% food intake reduction in preclinical studies with no GI side effects. Designed for oral, sublingual, or nasal non-injectable delivery. Patent-protected through 2042 (U.S. Patent Application 20220204581A1), exclusively licensed from Syracuse University.

Quantifiable outcome

  • ~15% body weight reduction in preclinical obese rat studies vs ~9% for liraglutide
  • +3 more outcomes

Companies that use SureNano Science

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

SureNano Science technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SureNano Science partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • LabCorpcoreImplementation/ SI/ Consulting Partner · 24 April 2026Collaboration with premier global CRO LabCorp for GLP-compliant toxicology and pharmacology studies for GEP-44. Studies covering rodents and non-rodent primates to determine MTD, safety margins, and biomarkers for first-in-human studies.
  • Academic Institutions and Research Groups (Ibogaine)minorStrategic or Co-development Partner · 24 April 2026Early-stage discussions to license or acquire IP related to synthesis, formulation, and delivery of Ibogaine and next-generation analogues for mental health and addiction treatment.
  • Investor Brand Network (IBN)minorGTM or Marketing Partner · 23 April 2026Six-month corporate communication and awareness strategy leveraging IBN's syndication network of over 5,000 media outlets, newsletters, social channels, and wire services. Quarterly cash consideration USD $29,000.
  • The Market Link (iHub)minorGTM or Marketing Partner · 23 April 2026Enhanced news release distribution with news blast and forum boost advertising campaign. One-time cash fee of USD $10,000 plus applicable taxes.
  • TDM Financial (Emerging Growth, LLC)minorGTM or Marketing Partner · 22 April 2026Six-month investor outreach and awareness campaign. Distribution of sponsored content across leading financial websites, social platforms (X, Reddit, TikTok, LinkedIn), and multimedia content production. Total cash consideration USD $26,667.
  • BTV (Milky Way Marketing Inc. and Blue Sun Productions Inc.)minorGTM or Marketing Partner · 23 February 2026Marketing and broadcast package including 30-second TV spot, TV ad spots, 40 BNN Bloomberg broadcasts, stock ticker ad, and newsletter eblast. Cash fee of $22,300 plus GST.
  • Emerald ScientificcoreChannel Partner/ Reseller/ Distributor · 1 January 2020Emerald Scientific launched the SureNano Emulsifier product in 2020, developed over two years. Product is 100% plant-derived stabilizing formula for high-performance nanoemulsions.
  • Syracuse UniversitycoreTechnology or IntegrationSyracuse University researchers, led by Dr. Robert Doyle, discovered GEP-44 peptide technology. SureNano acquired GlucaPharm which holds exclusive license from Syracuse University for GEP-44 development. Research supported by NIH and other US entities.
  • 1150641 B.C. Ltd.coreStrategic or Co-development PartnerJoint venture partner for development and marketing of SureNano powder nanoemulsion product. Each joint venturer contributed $30,000. Exclusive license agreements for Canada, Oklahoma, and Colorado.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

SureNano Science competitors and assessment

Company assessment

Direct peers

  • Viking Therapeutics: Clinical-stage biotech developing peptide therapeutics for metabolic disease, including VK2735 (a dual GLP-1/GIP receptor agonist) for obesity. Highly comparable to SureNano/GlucaPharm as a small-cap, differentiated-mechanism GLP-1 developer pursuing the same end-market.
  • Structure Therapeutics: Clinical-stage company developing oral small-molecule GLP-1 receptor agonists (e.g., GSBR-1290) for obesity and type 2 diabetes. Closely comparable to SureNano's GEP-44 strategy of pursuing a differentiated, non-injectable GLP-1 mechanism to compete with injectable incumbents.
  • Altimmune: Clinical-stage biopharmaceutical company developing peptide therapeutics for metabolic disease, including pemvidutide, a GLP-1/glucagon dual agonist for obesity. Comparable as a small-cap peptide metabolic disease developer with similar clinical-stage positioning to GlucaPharm.
  • Zealand Pharma: Denmark-based peptide therapeutics company developing multiple peptide candidates for metabolic disease and obesity, with a strong focus on differentiated mechanisms and non-injectable delivery. Directly comparable to GEP-44's peptide-mechanism, metabolic-disease focus.

Broad incumbents

  • Eli Lilly: Major pharmaceutical company and current market leader in the GLP-1 space with Mounjaro/Zepbound (tirzepatide, a dual GIP/GLP-1 agonist) and an extensive next-generation obesity/diabetes pipeline. Defines the competitive environment in which SureNano/GlucaPharm must compete.
  • Novo Nordisk: Global leader in GLP-1 therapy with Ozempic and Wegovy (semaglutide) plus an oral GLP-1 (Rybelsus) and deep next-gen pipeline. Sets the efficacy, tolerability, and commercial benchmarks that any GEP-44 must meet or exceed to succeed.
  • Croda International: Global specialty chemicals company producing high-performance surfactants, formulation ingredients, and delivery systems for personal care, food, and life sciences markets. Comparable to SureNano's legacy nanoemulsion/surfactant business on the non-pharma side.

Emerging players

  • Lexicon Pharmaceuticals: Small-cap clinical-stage biotech focused on small-molecule drug discovery for metabolic and neuropathic disease. Comparable as an emerging player with limited resources pursuing differentiated metabolic-disease mechanisms.
  • Soleno Therapeutics: Small-cap clinical-stage company developing therapeutics for rare metabolic disorders (e.g., Prader-Willi syndrome). Comparable profile to GlucaPharm as a micro-cap clinical-stage metabolic-disease developer with concentrated single-asset risk.

Others

  • Emerald Scientific: Distributor and channel partner that launched the SureNano Emulsifier product in 2020 and is a select customer for SureNano's surfactant line. Listed as an ecosystem/distribution peer rather than a competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

SureNano Science compliance and trust

Trust signal

Compliance5 records

SureNano Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SureNano Science leadership team

Management profile

Number of profiles

Profiles6 records

SureNano Science subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SureNano Science funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SureNano Science M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SureNano Science

What does SureNano Science do?

SureNano Science Ltd. is a publicly traded life sciences company operating two integrated lines: (1) a commercialized nanoemulsion surfactant platform — the FDA GRAS-approved, Health Canada-compliant SureNano Emulsifier and the in-development SureNano Powder — distributed through exclusive licenses in Canada and select US states; and (2) a pharmaceutical pipeline via its wholly owned subsidiary GlucaPharm Inc., anchored by GEP-44, a patented triple-agonist peptide (GLP-1 + Y1 + Y2) licensed from Syracuse University for obesity and metabolic disease, currently in FDA IND-enabling toxicology studies.

Is SureNano Science a public or private company?

SureNano Science is a public company. It is classified as public and is currently operating.

When was SureNano Science founded?

SureNano Science was founded in 2021. It employs 11 to 50 people.

Where is SureNano Science based?

SureNano Science is headquartered in Vancouver, Canada, in the North America region.

How does SureNano Science make money?

Three revenue lines are on record. Surfactant Product Sales are the primary driver. The others are pharmaceutical Licensing and Royalties and private Placement Financing.

Who are SureNano Science's main competitors?

Direct peers on record are Viking Therapeutics, Structure Therapeutics, Altimmune and Zealand Pharma. Broad incumbents are Eli Lilly, Novo Nordisk and Croda International. Emerging players are Lexicon Pharmaceuticals and Soleno Therapeutics. Emerald Scientific is listed as an others.

Does SureNano Science have an API?

No public API is recorded for SureNano Science.

What industry is SureNano Science in?

SureNano Science's product category is Pharmaceutical & Drug Delivery Systems. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Financial PostNetworkNews Audio Announces Audio Press Release (APR) Discussing Overcoming Limitations on First-Generation GLP-1 Drug TherapiesSureNano Science Ltd., a Canadian life sciences company listed on the CSE and OTCQB, announced that it is advancing GEP-44, a next-generation metabolic therapy developed at Syracuse University, as an alternative to first-generation GLP-1 drug therapies. GEP-44 functions as a triple agonist targeting GLP-1 and peptide YY receptors Y1 and Y2, and preclinical studies demonstrated meaningful reductions in food intake and body weight while improving glycemic control and reportedly avoiding the nausea and gastrointestinal side effects common with first-generation therapies. The company is now advancing this patented therapeutic candidate through the FDA pathway as it positions for the obesity and metabolic disease market.GlobeNewswireNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesSureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a patented next-generation triple agonist GLP-1 peptide therapy targeting obesity and metabolic disease, with preclinical data demonstrating approximately 15% body weight reduction and 39% food intake reduction compared to first-generation GLP-1 drugs. The global GLP-1 market is projected to reach $190 billion by 2035, creating significant commercial opportunity for differentiated therapeutic candidates that address tolerability and delivery limitations of current treatments. The company is also pursuing oral, sublingual, and intranasal delivery technologies to expand patient accessibility while evaluating early-stage opportunities in ibogaine-related delivery technologies.Financial PostThe Next Generation of the GLP-1 Revolution Is Already UnderwaySureNano Science is advancing GEP-44, a preclinical GLP-1 compound, through IND-enabling studies, claiming approximately 15% weight loss in preclinical testing versus 9% for liraglutide, alongside developing oral and non-invasive drug delivery technologies. The article also covers recent GLP-1 sector developments including Eli Lilly's FDA approval of oral obesity drug Foundayo, Novo Nordisk's launch of oral Ozempic tablets, Amgen's phase 2 MariTide results, and Pfizer's positive phase 2b VESPER-3 trial data for monthly injectable PF'3944. These announcements underscore intensifying competition in the obesity and diabetes treatment market as developers pursue improved efficacy, tolerability, and patient accessibility.Stock TitanSureNano Plans GEP-44 GLP Studies, Ibogaine IP TalksSureNano Science Ltd. announced the planning of FDA IND-enabling GLP toxicology and pharmacology studies for its lead candidate GEP-44, a GLP-1 agonist peptide targeting obesity and Type II diabetes, to be conducted in collaboration with LabCorp across rodents and non-rodent primates to determine safety margins and maximum tolerated dose for first-in-human studies. The company also disclosed it has entered early-stage discussions to license or acquire intellectual property related to Ibogaine and next-generation analogues, coinciding with recent FDA IND clearance for Ibogaine and a U.S. executive order supporting psychedelic research. Additionally, SureNano entered multiple investor relations and marketing service agreements with TDM Financial, IBN, The Market Link, and BTV totaling approximately $88,000 in fees over six-month campaigns.NewsfileSureNano Science Initiates FDA Stage GLP Toxicology and Pharmacology Studies for GLP GEP-44 and Enters Discussions to Acquire Ibogaine Formulation IP PortfolioSureNano Science announced a GLP-compliant toxicology and pharmacology study program for its lead candidate GEP-44, to be conducted with LabCorp. The studies aim to support an FDA Phase I trial in Australia. The company also initiated discussions to acquire Ibogaine formulation IP.NewsfileSureNano Closes FinancingSureNano Science Ltd. closed a private placement of 2,450,000 common shares at $0.10 each, raising $245,000 in cash and $85,000 in debt conversion. The proceeds will fund operating expenses, legal and audit fees, and working capital. The shares carry a four-month and a day hold period.NewsfileSureNano Announces Closing of $1,250,000 Private PlacementSureNano Science Ltd. closed a non-brokered private placement raising $1,250,000 through the issuance of 10,000,000 units at $0.125 per unit, with each unit comprising one common share and one warrant exercisable at $0.35 for 24 months. The company paid finders $75,000 in cash commissions and issued 600,000 finder's warrants as consideration for introducing subscribers to the placement. Proceeds will be used for operating expenses, legal and audit fees, exploring new markets for the SureNano surfactant, and evaluating potential business combinations with complementary companies.NewsfileSureNano Announces Private PlacementSureNano Science Ltd. announced a private placement financing of up to $1,250,000 through the sale of up to 10,000,000 units at $0.125 per unit, with each unit comprising one common share and one warrant exercisable at $0.35 per share for 24 months. The company plans to use the proceeds for operating expenses, including legal and audit fees, and to explore new markets for its SureNano™ surfactant product. All securities issued will be subject to a four-month-and-one-day hold period.YahooSureNano Closes FinancingSureNano Science Ltd. closed a private placement of 2,450,000 common shares at $0.10 each, raising $245,000 in cash plus $85,000 in debt conversion. The proceeds will fund operating expenses, legal and audit fees, and working capital. The shares carry a four-month and a day hold period.